Divi's Laboratories is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and custom synthesis services for global markets. The company operates with very low debt and has recently shown strong growth in both revenue and earnings.
The company benefits from its massive scale in API manufacturing and strong relationships with global pharmaceutical giants for custom research. A very low Beta suggests the stock is significantly less volatile than the broader market, offering stability during uncertain times.
The stock is currently trading at a high Price-to-Earnings (PE) ratio of over 90, which may indicate that the valuation is stretched compared to historical averages. Additionally, as an export-oriented unit, the company remains sensitive to global regulatory changes and currency fluctuations.
For beginners, the company’s near-zero debt and consistent profitability make it a relatively stable entry point into the healthcare sector. However, new investors should be cautious of the high valuation and consider the impact of its low dividend yield on total returns.
The long-term outlook is supported by the global shift toward diversified supply chains (China plus one strategy) in the pharmaceutical industry. The company's focus on high-margin custom synthesis provides a sustainable competitive advantage for patient investors.
In the Futures and Options segment, the stock’s low Beta implies slower price movements, which may result in lower premiums for option sellers. Beginners should avoid F&O due to high leverage and complexity, as these instruments are generally unsuitable for wealth creation compared to long-term equity holding.
Headlines from across the web, sentiment-scored by AI.
India's CRDMO sector growth rebounded to 19% YoY in Q1FY27 versus just 9% YoY in the March 2026 quarter, marking the highest growth level since the December...
Divi's Laboratories Limited has fixed July 24, 2026, as the record date for a ₹30 per share dividend, subject to approval at the 36th AGM on August 10,...
Divi's Laboratories Share Price hit a fresh 52-week high at Rs 8680. Read price action, valuation, sector and peer analysis.
# NSE IPO 2026: Will it be the biggest IPO in India? ## Most Read News ### [Stock Market Today: Sensex, Nifty 50 Fall Amid Rising Crude Oil Prices, Middle East Tensions](https://www.indiainfoline.com/news/markets/stock-market-today-sensex-nifty-50-fall-amid-rising-crude-oil-prices-middle-east-tensions) - [Divis Laboratories Ltd](https://www.indiainfoline.com/company/divis-laboratories-ltd-share-price)
## Introduction ### Top 14 Pharma Stocks in India 2026 | | | | | | | | | | | | |-|-|-|-|-|-|-|-|-|-|-| | Divi’s Laboratories Ltd. | 6299.65 | 167235.91 | 11.61 | 36.04 | 3.07 | 66.42 | 16.51 | 0.00 | 15.57 | 20.65 |
# Ahead of Market: 10 things that will decide stock market action on Wednesday ### Live Events Among the ones which hit their 52-week highs on NSE included Paytm, Divis Labs, AU Small Finance Bank, Bajaj Auto, IPCA Labs, PVR Inox and HFCL.
Dr. Reddy's Laboratories is an Indian pharmaceutical company that was founded in 1984 by Kallam Anji Reddy. Headquartered in Hyderabad, the company produces...
# Mcap of 4 of top-10 most valued firms erodes ₹87,960 cr, Airtel worst hit ## Last week, the BSE benchmark Sensex declined 468.42 points, or 0.60 per cent, and the NSE Nifty dipped 114 points, or 0.46 per cent ### Also Read [\ **Laurus joins ₹1 trillion market cap club as stock zooms 120% in 1 year**](https://www.business-standard.com/markets/news/laurus-labs-share-price-joins-1-trillion-market-cap-club-as-stock-zooms-120-in-1-year-126080600619_1.html) [\ **Divi's Labs rallies 5% on strong Q1; surpasses Eicher, Hindalco in mcap**](https://www.business-standard.com/markets/news/divi-s-labs-share-price-rallies-5-on-strong-q1-surpasses-eicher-hindalco-in-mcap-126080300414_1.html)